Literature DB >> 10213490

Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer.

W Wu1, B L Kemp, M L Proctor, A F Gazdar, J D Minna, W K Hong, L Mao.   

Abstract

DMBT1 is a candidate tumor suppressor gene located at 10q25.3-26.1. Homozygous deletion of the gene was found in a subset of medulloblastoma and glioblastoma multiforme; lack of expression was noted in the majority of these tumors. In adult tissues, DMBT1 is highly expressed only in lung and small intestine tissues, indicating its important role in these organs. By analyzing lung cancer cell lines and primary lung tumors using reverse transcription-PCR, we found that 100% (20 of 20) of small cell lung cancer (SCLC) cell lines and 43% (6 of 14) of non-small cell lung cancer (NSCLC) cell lines lacked DMBT1 expression. Furthermore, 45% (9 of 20) of the primary NSCLCs exhibited a markedly low level of gene expression compared with corresponding normal lung tissues, indicating that lack of gene expression also occurs in primary lung cancers. To determine the potential mechanisms for lack of DMBT1 expression in lung cancer, we analyzed tumor cell lines for potential intragenic homozygous deletions of the gene and found such homozygous deletions in 10% (4 of 40) of SCLC cell lines but in none of 14 NSCLC cell lines. Moreover, the loss of expression could not be rescued by treatment with a demethylation agent (5-azacytidine) in two NSCLC cell lines lacking DMBT1 expression, suggesting that de novo methylation of the promoter region of the gene is unlikely to play a role in inactivation of the gene. We then sequenced the whole coding region of DMBT1 in 8 NSCLC cell lines that expressed DMBT1 and 20 primary NSCLCs. A potential point mutation at codon 52 was detected in a NSCLC cell line and resulted in an amino acid change from serine to tryptophan. Three common polymorphisms were also detected in tissues analyzed. Our data demonstrate that DMBT1 expression is frequently lost in lung cancer due to gene deletion and to other not yet identified mechanisms, suggesting that inactivation of DMBT1 may play an important role in lung tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213490

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.

Authors:  H Sasaki; M C Zlatescu; R A Betensky; Y Ino; J G Cairncross; D N Louis
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Scientific frontiers: emerging technologies for salivary diagnostics.

Authors:  B J Baum; J R Yates; S Srivastava; D T W Wong; J E Melvin
Journal:  Adv Dent Res       Date:  2011-10

4.  The scavenger receptor, cysteine-rich domain-containing molecule gp-340 is differentially regulated in epithelial cell lines by phorbol ester.

Authors:  W Kang; O Nielsen; C Fenger; J Madsen; S Hansen; I Tornoe; P Eggleton; K B M Reid; U Holmskov
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

5.  Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D.

Authors:  U Holmskov; J Mollenhauer; J Madsen; L Vitved; J Gronlund; I Tornoe; A Kliem; K B Reid; A Poustka; K Skjodt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

6.  Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas.

Authors:  Kinya Terada; Takashi Tamiya; Shigeru Daido; Hirokazu Kambara; Hiroaki Tanaka; Yasuhiro Ono; Kengo Matsumoto; Sachio Ito; Mamoru Ouchida; Takashi Ohmoto; Kenji Shimizu
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

7.  Dissecting characteristics and dynamics of differentially expressed proteins during multistage carcinogenesis of human colorectal cancer.

Authors:  Fang Peng; Ying Huang; Mao-Yu Li; Guo-Qing Li; Hui-Chao Huang; Rui Guan; Zhu-Chu Chen; Song-Ping Liang; Yong-Heng Chen
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

8.  Genetic mapping in mice identifies DMBT1 as a candidate modifier of mammary tumors and breast cancer risk.

Authors:  Anneke C Blackburn; Linda Z Hill; Amy L Roberts; Jun Wang; Dee Aud; Jimmy Jung; Tania Nikolcheva; John Allard; Gary Peltz; Christopher N Otis; Qing J Cao; Reva St J Ricketts; Stephen P Naber; Jan Mollenhauer; Annemarie Poustka; Daniel Malamud; D Joseph Jerry
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

9.  Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers.

Authors:  Josane F Sousa; Amy-Joan L Ham; Corbin Whitwell; Ki Taek Nam; Hyuk-Joon Lee; Han-Kwang Yang; Woo Ho Kim; Bing Zhang; Ming Li; Bonnie LaFleur; Daniel C Liebler; James R Goldenring
Journal:  Am J Pathol       Date:  2012-09-01       Impact factor: 4.307

10.  Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer.

Authors:  Bolin Chen; Min Yang; Kang Li; Jia Li; Li Xu; Fang Xu; Yan Xu; Dandan Ren; Jiao Zhang; Liyu Liu
Journal:  Oncol Lett       Date:  2021-05-19       Impact factor: 3.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.